162 related articles for article (PubMed ID: 36733091)
1. [A Case of GIST of Stomach with Peritoneal Dissemination-Long-Term Survival with Imatinib and Surgical Resection].
Nakata K; Masuzawa T; Katsuyama S; Sugimura K; Ikeshima R; Kawai K; Hiraki M; Shinke G; Katsura Y; Ohmura Y; Hata T; Takeda Y; Murata K
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1429-1430. PubMed ID: 36733091
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Recurrent Gastric GIST Who Survived for Long after Laparoscopic Resection and Imatinib Therapy].
Yabe N; Takenoya T; Oto I; Harada Y; Kondo A; Ogiso M; Maeda H; Asada Y; Sako H; Yoshikawa T; Osumi K; Kamiya N; Sotome K; Ishii Y; Watanabe M
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1718-1720. PubMed ID: 38303184
[TBL] [Abstract][Full Text] [Related]
4. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
5. Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report.
Tjhoi WEH; Li K; Shou CH; Yang WL; Yu JR
Medicine (Baltimore); 2019 Feb; 98(6):e14477. PubMed ID: 30732216
[TBL] [Abstract][Full Text] [Related]
6. Laparoscopic resection for imatinib-resistant recurrent tumors of gastric gastrointestinal stromal tumors: A case report.
Sekiguchi N; Takahashi T; Nakajima K; Kurokawa Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Eguchi H; Doki Y
Asian J Endosc Surg; 2022 Jul; 15(3):638-641. PubMed ID: 35108756
[TBL] [Abstract][Full Text] [Related]
7. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H
Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
[TBL] [Abstract][Full Text] [Related]
8. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
Qi J; Liu HL; Ren F; Liu S; Shi W; Liu WH; Cai GQ; Liao GQ
World J Surg Oncol; 2020 Apr; 18(1):70. PubMed ID: 32264886
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
10. Giant gastric gastrointestinal stromal tumor with severe peritoneal dissemination controlled by imatinib therapy following debulking surgery: a case report.
Fukuda S; Fujiwara Y; Wakasa T; Kitani K; Tsujie M; Yukawa M; Ohta Y; Inoue M
J Med Case Rep; 2017 Feb; 11(1):33. PubMed ID: 28166823
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK
Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
[TBL] [Abstract][Full Text] [Related]
12. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
Wu X; Li J; Xu W; Gao J; Li Y; Shen L
Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
[TBL] [Abstract][Full Text] [Related]
13. [Significance of surgical treatment for recurrent and metastatic gastrointestinal stromal tumors].
Zhang XH; He YL
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):840-844. PubMed ID: 32927506
[TBL] [Abstract][Full Text] [Related]
14. Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.
Farag S; van der Kolk LE; van Boven HH; van Akkooi ACJ; Beets GL; Wilmink JW; Steeghs N
Fam Cancer; 2018 Apr; 17(2):247-253. PubMed ID: 28710566
[TBL] [Abstract][Full Text] [Related]
15. [A Case of Peritoneal Metastasis Resection from GIST of the Small Intestine with Focal Resistance Against Imatinib Mesylate].
Ono T; Tanaka N; Suzuki H; Imoto H; Yamamura A; Karasawa H; Kohyama A; Aoki T; Watanabe K; Ohnuma S; Musha H; Motoi F; Kamei T; Naitoh T; Unno M
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2452-2454. PubMed ID: 32156962
[TBL] [Abstract][Full Text] [Related]
16. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
17. [A Case of Gastrointestinal Stromal Tumor Re-Resected Ten Years after the Resection of Its Recurrence].
Aida T; Shiobara M; Wakatsuki K; Ogasawara T; Suda K; Miyazawa K; Miyoshi T; Sato S; Yoshioka S; Yamazaki K
Gan To Kagaku Ryoho; 2019 Dec; 46(13):1943-1944. PubMed ID: 32157020
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal stromal tumors: imatinib and beyond.
Schnadig ID; Blanke CD
Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
[TBL] [Abstract][Full Text] [Related]
19. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).
Rubió-Casadevall J; Martinez-Trufero J; Garcia-Albeniz X; Calabuig S; Lopez-Pousa A; Del Muro JG; Fra J; Redondo A; Lainez N; Poveda A; Valverde C; De Juan A; Sevilla I; Casado A; Andres R; Cruz J; Martin-Broto J; Maurel J;
Ann Surg Oncol; 2015 Sep; 22(9):2948-57. PubMed ID: 25608769
[TBL] [Abstract][Full Text] [Related]
20. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
